Summit Therapeutics (SMMT) Stock News
$SMMT · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Summit Therapeutics (SMMT) in the past 30 days, 1 of it high impact. BORSA’s news read on SMMT is bullish at 59/100, unchanged over 24 hours, based on 1 company event over the past 30 days. Summit Therapeutics’ next earnings report is scheduled for Monday, Oct 19.
The wire on $SMMT
newest first · updated · direct subject stories onlyAstraZeneca invests $2 billion in Summit Therapeutics, plans cancer drug collaboration
AstraZeneca will purchase $2 billion in convertible preferred shares of Summit Therapeutics at $18.36 per share, a 10% premium. The companies also agreed to collaborate on clinical trials combining ivonescimab with AstraZeneca's ADC portfolio.
bullish 85 · impact 80